Treatment of Secondary Spontaneous Pneumothorax Complicating Silicosis and Progressive Massive Fibrosis.

Abstract

Summary: To clarify the management and treatment for the refractory cases of secondary spontaneous pneumothorax (SSP), we analyzed the clinical features in SSP complicating three cases of advanced silicosis, and discussed the available treatment. All three cases were males of age ranging from 60 to 70 years, and had silicosis with massive progressive fibrosis (PMF), classified as type 4 (PR4) according to the ILO guidelines. There was no correlation between the onset of SSP and the smoking habit, or the duration of the occupational exposure to silica. In a total of ten episodes of SSP, a refractory episode occurred in each of the three patients. No surgical treatment was possible because of some complications. Therefore, we administered conservative treatments under mechanical ventilation. The conservative treatments used were tube drainage with suction in each episode and pleurodesis by the combination of minocycline and OK-432 in one case. Approximately one month was the average time required for the air leak cessation. A significant decline in arterial oxygen tension (Pa02) was observed after the treatment of one case, suggesting further respiratory deterioration. These results imply that the more aggressive treatments for refractory SSP should be limited because of the patient status and progression. More information might be required before performing these options safely and effectively.

Do bullae and emphysema increase risk of pneumothorax in silicosis?

“…[24] Our findings support this hypothesis as shown in Table 1. According to an investigation by Bahrami and Mahjub in the stone-grinding factories where the study subjects had been employed, the concentration of silica compounds in the ambient air had been 25-50% higher than Occupational Safety and Health Administration (OSHA) levels.…”

Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non‐small cell lung cancer

“…OK432, a sclerosing agent used only in certain parts of Asia, has been used for the treatment of malignant pleural effusion, 16,23 , 24 pneumothorax 27 and chylothorax 28 . Although the efficacy of monotherapy with OK432 for pleurodesis of malignant pleural effusion has been evaluated, 16 this study showed that the efficacy was further improved when it was used in combination with cisplatin.…”

Do bullae and emphysema increase risk of pneumothorax in silicosis?

“…In a case series study, Kawano et al suggested that there was no correlation between the onset of SSP and duration of occupational exposure to silica [ 24 ]. Our findings support this hypothesis as shown in Table 1 .…”